`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`MYLAN PHARMACEUTICALS INC., TEVA PHARMACEUTICALS USA,
`INC. and AKORN INC., 1
`Petitioners,
`
`V.
`
`ALLERGAN, INC.
`Patent Owner.
`
`Case IPR2016-01127 (8,685,930 B2)
`Case IPR2016-01128 (8,629,111 B2)
`Case IPR2016-01129 (8,642,556 B2)
`Case IPR2016-01130 (8,633,162 B2)
`Case IPR2016-01131 (8,648,048 B2)
`Case IPR2016-01132 (9,248,191 B2)
`
`PETITIONER MYLAN PHARMACEUTICALS INC.’S MANDATORY
`
`CHANGE-OF-INFORMATION NOTICES
`
`1 Cases IPR2017-00576 and IPR2017-00594, IPR2017-00578 and IPR2017-
`00596, IPR2017-00579 and IPR2017-00598, IPR2017-00583 and IPR2017-00599,
`
`IPR2017-00585 and IPR2017-00600, and IPR2017-00586 and IPR2017-00601,
`have respectively been joined with the captioned proceedings. The word-for-Word
`identical paper is filed in each proceeding identified in the caption pursuant to the
`Board’s Scheduling Order (Paper 10).
`
`
`
`Pursuant to 37 C.F.R. § 42.8(a)(3), the undersigned on behalf of and acting
`
`in a representative capacity for Petitioner Mylan Pharmaceuticals Inc. (“Mylan”),
`
`hereby submits the following mandatory change-of-information notices in
`
`connection With the inter partes reviews identified in the caption.
`
`A.
`
`Real Party-In-Interest (37 C.F.R. § 42.8(b)(1)) — Unchanged
`
`B.
`
`Related Matters (37 C.F.R. § 42.8(b)(2)) — Revised
`
`Allergan, Inc. v. Teva Pharm. USA, Inc., No. 2018-1 130 (Fed. Cir.)
`
`(invalidity affirmed November 13, 2018) (EX1 163-65; EX1 172);
`
`Allergan, Inc. v. Deva Holding A.S., No. 2:16-cv-1447 (E.D. TeX.) (filed
`
`December 22, 2016);
`
`Allergan, Inc. v. Saptalis Pharmaceuticals, LLC, No. 1:18-cv-01231 (D.
`
`Del.) (filed August 10, 2018);
`
`Allergan, Inc. v. Amneal Pharmaceuticals LLC, No. 1:18-cv-01457 (D. Del.)
`
`(filed September 20, 2018);
`
`St. Regis Mohawk Tribe v. Mylan Pharmaceuticals Inc., No. 2018-1638
`
`(Fed. Cir.) (stay pending petition for certiorari denied November 13, 2018).
`
`US. Patent Application No. 15/585,320 (filed May 3, 2017).
`
`C.
`
`Lead and Back-up Counsel (37 C.F.R. § 42.8(b)(3)) — Unchanged
`
`D.
`
`Electronic Service — Unchanged
`
`
`
`Dated: November 21, 2018
`
`Respectfully submitted,
`
`/ Steven Parmelee /
`Steven W. Parmelee
`
`Reg. No. 31,990
`
`
`
`CERTIFICATE OF SERVICE
`
`This is to certify that I caused to be served a true and correct copy of the
`
`foregoing Petitioner Mylan Pharmaceuticals Inc.’s Mandatory Change-of-
`
`Information Notices on this 21th day of November, 2018, on the Patent Owner at
`
`the correspondence address of Allergan, Inc. and St. Regis Mohawk Tribe as
`
`follows:
`
`Dorothy P. Whelan
`Michael Kane
`
`Susan Morrison Colletti
`
`Robert M. Oakes
`
`Jonathan Singer
`Fish & Richardson PC.
`
`3200 RBC Plaza
`
`60 South Sixth Street
`
`Minneapolis, MN 55402
`Email: IPR13351-0008IP1@fr.com
`Email: IPR13351-0008IP2@fr.com
`Email: IPR13351-0008IP3@fr.com
`Email: IPR13351-0008IP4@fr.com
`Email: IPR13351-0008IP5@fr.com
`Email: IPR13351-0008IP6@fr.com
`Email: PTABInbound@fr.com
`
`Alfonso Chan
`
`Joseph DePumpo
`Michael W. Shore
`
`Christopher L. Evans
`Shore Chan DePumpo LLP
`901 Main Street, Suite 3300
`
`Dallas, TX 75201
`Email: achan@shorechan.com
`Email: jdepumpo@shorechan.com
`Email: mshore@shorechan.com
`Email: cevans@shorechan.com
`
`
`
`And on the remaining petitioners as follows:
`
`Gary Speier
`Mark Schuman
`
`CARLSON, CASPERS, VANDENBURGH,
`
`LINDQUIST & SCHUMAN, PA.
`225 South Sixth Street, Suite 4200
`Minneapolois, MN 55402
`Email: gspeier@carlsoncaspers.com
`Email: mschuman@carlsoncasp_ers.com
`Attorneys for Teva Pharmaceuticals USA, Inc.
`
`Michael Dzwonczyk
`Azadeh Kokabi
`
`Travis Ribar
`
`SUGHRUE MION, PLLC
`2100 Pennsylvania Ave., NW
`Washington, DC 20037
`Email: mdzwonczyk@sughrue.com
`Email: akokabi@sughrue.com
`Email: tribar@sughrue.com
`Attorneys for Akorn Inc.
`
`Respectfully submitted,
`
`Dated: November 21, 2018
`
`/ Steve Parmelee /
`
`Steven W. Parmelee, Lead Counsel
`
`Reg. No. 31,990
`
`